Syndax Pharmaceuticals Inc (SNDX) stock
SNDXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$9.20+0.07 (+0.77%)
Close on Nov 17, 2026Market cap $821.53MP/E –Yield –
Syndax Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Syndax Pharmaceuticals's cash was $427.10M at Sep 30, 2026. For fiscal 2025 it was $394.07M, down 31.2% from the year before. Over ten years it grew 16.4% a year on average. The highest annual figure on record is $572.88M in fiscal 2024.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $394.07M | -31.2% |
| FY2024 | Dec 31, 2024 | $572.88M | +0.4% |
| FY2023 | Dec 31, 2023 | $570.70M | +19.9% |
| FY2022 | Dec 31, 2022 | $475.80M | +8.2% |
| FY2021 | Dec 31, 2021 | $439.94M | +50.1% |
| FY2020 | Dec 31, 2020 | $293.07M | +390.3% |
| FY2019 | Dec 31, 2019 | $59.78M | -26.1% |
| FY2018 | Dec 31, 2018 | $80.91M | -37.7% |
| FY2017 | Dec 31, 2017 | $129.97M | +23.4% |
| FY2016 | Dec 31, 2016 | $105.33M | +21.8% |
| FY2015 | Dec 31, 2015 | $86.49M | +764.1% |
| FY2014 | Dec 31, 2014 | $10.01M | -0.9% |
| FY2013 | Dec 31, 2013 | $10.10M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $427.10M | -2.0% |
| Q2 FY2026 | Jun 30, 2026 | $547.86M | +20.3% |
| Q1 FY2026 | Mar 31, 2026 | $352.06M | -31.3% |
| Q4 FY2025 | Dec 31, 2025 | $394.07M | -31.2% |
| Q3 FY2025 | Sep 30, 2025 | $435.98M | +11.9% |
| Q2 FY2025 | Jun 30, 2025 | $455.23M | +7.1% |
| Q1 FY2025 | Mar 31, 2025 | $512.20M | +17.9% |
| Q4 FY2024 | Dec 31, 2024 | $572.88M | +0.4% |
| Q3 FY2024 | Sep 30, 2024 | $389.61M | +7.2% |
| Q2 FY2024 | Jun 30, 2024 | $425.10M | +6.6% |
| Q1 FY2024 | Mar 31, 2024 | $434.58M | +0.5% |
| Q4 FY2023 | Dec 31, 2023 | $570.70M | +19.9% |
| Q3 FY2023 | Sep 30, 2023 | $363.56M | +7.6% |
| Q2 FY2023 | Jun 30, 2023 | $398.80M | +8.7% |
| Q1 FY2023 | Mar 31, 2023 | $432.39M | +8.7% |
| Q4 FY2022 | Dec 31, 2022 | $475.80M | +8.2% |
| Q3 FY2022 | Sep 30, 2022 | $337.84M | +47.1% |
| Q2 FY2022 | Jun 30, 2022 | $366.79M | +44.9% |
| Q1 FY2022 | Mar 31, 2022 | $397.93M | +46.7% |
| Q4 FY2021 | Dec 31, 2021 | $439.94M | +50.1% |
| Q3 FY2021 | Sep 30, 2021 | $229.71M | +35.0% |
| Q2 FY2021 | Jun 30, 2021 | $253.13M | +35.5% |
| Q1 FY2021 | Mar 31, 2021 | $271.34M | +174.1% |
| Q4 FY2020 | Dec 31, 2020 | $293.07M | +390.3% |
| Q3 FY2020 | Sep 30, 2020 | $170.16M | +135.6% |
| Q2 FY2020 | Jun 30, 2020 | $186.75M | +131.9% |
| Q1 FY2020 | Mar 31, 2020 | $99.01M | +6.8% |
| Q4 FY2019 | Dec 31, 2019 | $59.78M | -26.1% |
| Q3 FY2019 | Sep 30, 2019 | $72.24M | -19.4% |
| Q2 FY2019 | Jun 30, 2019 | $80.52M | -18.2% |
| Q1 FY2019 | Mar 31, 2019 | $92.74M | -18.1% |
| Q4 FY2018 | Dec 31, 2018 | $80.91M | -37.7% |
| Q3 FY2018 | Sep 30, 2018 | $89.60M | -25.7% |
| Q2 FY2018 | Jun 30, 2018 | $98.39M | -24.3% |
| Q1 FY2018 | Mar 31, 2018 | $113.20M | +21.7% |
| Q4 FY2017 | Dec 31, 2017 | $129.97M | +23.4% |
| Q3 FY2017 | Sep 30, 2017 | $120.59M | – |
| Q2 FY2017 | Jun 30, 2017 | $129.96M | – |
| Q1 FY2017 | Mar 31, 2017 | $93.00M | – |
| Q4 FY2016 | Dec 31, 2016 | $105.33M | – |
See a number that looks wrong?